Basiliximab

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Simulect; Belgium: Simulect; Cyprus: Simulect; Czech Republic: Simulect; Denmark: Simulect; Estonia: Simulect; Finland: Simulect; France: Simulect; Germany: Simulect; Greece: Simulect; Hungary: Simulect; Ireland: Simulect; Italy: Simulect; Latvia: Simulect; Lithuania: Simulect; Luxembourg: Simulect; Malta: Simulect; Netherlands: Simulect; Poland: Simulect; Portugal: Simulect; Romania: Simulect; Slovakia: Simulect; Slovenia: Simulect; Spain: Simulect; Sweden: Simulect; UK: Simulect.

North America

Canada: Simulect; USA: Simulect.

Latin America

Argentina: Simulect; Brazil: Simulect; Mexico: Simulect.

Asia

Japan: Simulect.

Drug combinations

Chemistry

Basiliximab: (1) Immunoglobulin G~1~, anti-(human interleukin 2 receptor)(human-mouse monoclonal CHI621 γ1-chain), disulfide with human-mouse monoclonal CHI621 light chain, dimer; (2) Immunoglobulin G~1~ (human-mouse monoclonal CHI621 heavy chain antihuman interleukin 2 receptor), disulfide with human-mouse monoclonal CHI621 light chain, dimer. CAS-179045-86-4 (1998).

Pharmacologic Category

Immunosuppressive Agents; Monoclonal Antibody. (ATC-Code: L04AC02).

Mechanism of action

Blocks the α-chain of the interleukin-2 (IL-2) receptor complex expressed on activated T lymphocytes.

Therapeutic use

Prophylaxis of acute organ rejection in renal transplantation.

Pregnancy and lactiation implications

Use in pregnant women only when benefit exceeds potential risk to the fetus. Use not recommended during lactation.

Unlabeled use

Contraindications

Hypersensitivity to basiliximab, murine proteins, or any component of the formulation.

Warnings and precautions

Severe hypersensitivity reactions may occur (within 24 hours). Human antimurine antibodies may be developed. The incidences of lymphoproliferative disorders or opportunistic infections may be increased. Should be used as a component of immunosuppressive regimen (including cyclosporine and corticosteroids).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart